1
项与 Targeted Neoantigen Haploidentical T Cell Injection(BGI Genomics) 相关的临床试验A Clinical Study to Evaluate the Safety, Tolerability and Initial Efficacy of Targeted Haploidentical Neoantigen T Cell Injection (hNeo-T) in the Treatment of Relapsed or Refractory EBV-positive T-cell Lymphoma
Objective: To evaluate the safety and tolerability of hNeo-T injection in patients with relapsed or refractory EBV-positive T-cell lymphoma.
Secondary objective: To evaluate the effectiveness of hNeo-T injection, and to evaluate the objective response rate (ORR) and disease control rate (DCR) by Lugano2014 criteria; Progression-free survival (PFS), duration of response (DOR), and overall survival (OS ) followed.
Objective of the exploratory study: To investigate the in vivo process of hNeo-T injection and describe the activity and related biological functions of hNeo-T cells in vivo, including but not limited to.
100 项与 Targeted Neoantigen Haploidentical T Cell Injection(BGI Genomics) 相关的临床结果
100 项与 Targeted Neoantigen Haploidentical T Cell Injection(BGI Genomics) 相关的转化医学
100 项与 Targeted Neoantigen Haploidentical T Cell Injection(BGI Genomics) 相关的专利(医药)
100 项与 Targeted Neoantigen Haploidentical T Cell Injection(BGI Genomics) 相关的药物交易